A recent report by Ruiz-Saenz et al. demonstrated that in BRAFV600E colorectal tumors, the compensatory SRC activation is the driving force behind the development of resistance to the inhibitors against BRAF and epidermal growth factor receptor (EGFR) after long-term management [54]. Here, SRC is linked to colorectal neoplasm.